07:42 AM EDT, 09/18/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Wednesday that its Fasenra (benralizumab) was approved by the US Food and Drug Administration for treating adult patients with eosinophilic granulomatosis with polyangiitis, a rare and potentially fatal immune-mediated vasculitis.

The approval was based on results from a late-stage trial, where nearly 60% of patients treated with Fasenra achieved remission, with 41% fully tapered off oral corticosteroids, AstraZeneca ( AZN ) said.

Price: 78.35, Change: -0.18, Percent Change: -0.23